drugset / Trial / NCT00652379
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Completed
18 enrolled
University of Aarhus
Aarhus University Hospital · collabAarhus University Hospital Skejby · collabThe Research Council for Health and Disease, Denmark · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-11
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanreotide | Other / unclassified | — | — |
| Subject | Octreotide | Peptide | — | — |
| Subject | Pegvisomant | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | Pegvisomant | Protein / enzyme biologic | 30 mg | Subcutaneous |